Hướng nghiên cứu hiện tại cho ung thư cổ tử cung giai đoạn khu vực tiến triển

Keys HM, Bundy BN, Stehman FB, et al.: Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999, 340:1154–1161. One of five seminal chemoradiotherapy trials that set the standard for treatment of locally advanced cervix cancer. Whitney CW, Sause W, Bundy BN, et al.: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999, 17:1339–1348. The second of five important chemoradiotherapy trials in this disease. Rose PG, Bundy BN, Watkins EB, et al.: Concurrent cisplatinbased chemoradiation in locally advanced cervical cancer. N Engl J Med 1999, 340:1144–1153. The third of five important chemoradiotherapy trials in this disease. Morris M, Eifel PJ, Lu J, et al.: Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med 1999, 340:1137–1143. The fourth of five important chemoradiotherapy trials in this disease. Peters WA III, Liu PY, Barrett RJ II, et al.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18:1606–1613. The last of five important chemoradiotherapy trials in this disease. Lehman M, Thomas G: Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer? Int J Gynecol Cancer 2001, 11:87–99. The authors provide a critical review of the reasons for failure of primary radiotherapy in locally advanced cervix cancer and raise a number of issues that should be addressed by future clinical trials. Christensen GE, Carlson B, Chao KS, et al.: Image-based dose planning of intracavitary brachytherapy: registration of serial-imaging studies using deformable anatomic templates. Int J Radiat Oncol Biol Phys 2001, 51:227–243. Quint S, de Boer HC, van Sornsen de Koste JR, et al.: Set-up verification of cervix cancer patients treated with long treatment fields: implications of a non-rigid bony anatomy. Radiother Oncol 2001, 60:25–29. Fellner C, Potter R, Knocke TH, Wambersie A: Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. Radiother Oncol 2001, 58:53–62. A critical comparison of CT treatment planning with standard radiographic treatment planning. Sood BM, Gorla G, Gupta S, et al.: Two fractions of high-doserate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys 2002, 53:702–706. Ferrigno R, dos Santos Novaes PE, Pellizzon AC, et al.: Highdose-rate brachytherapy in the treatment of uterine cervix cancer: analysis of dose effectiveness and late complications. Int J Radiat Oncol Biol Phys 2001, 50:1123–1135. Fyles A, Milosevic M, Hedley D, et al.: Tumor hypoxia has independent predictor impact only in patients with nodenegative cervix cancer. J Clin Oncol 2002, 20:680–687. Milosevic M, Fyles A, Hedley D, et al.: Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001, 61:6400–6405. West CML, Cooper RA, Loncaster JA, et al.: Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 2001, 61:2907–2910. Grogan M, Thomas GM, Melamed I, et al.: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999, 86:1528–1536. This paper critically reviews the value of hemoglobin level and response to radiotherapy in a retrospective analysis and sets the direction for development of a clinical trial designed to determine whether maintenance of normal hemoglobin level during radiotherapy improves the clinical result. Kapp KS, Poschauko J, Geyer E, et al.: Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2002, 54:58–66. Kavanagh BD, Fischer BA IV, Segreti EM, et al.: Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 2001, 51:435–441. Dowdy SC, Boardman CH, Wilson TO, et al.: Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol 2002, 186:1167–1173. Long HJ III, Rayson S, Podratz KC, et al.: Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol 2002, 25:547–551. MacLeod C, O’Donnell A, Tattersall MH, et al.: Locally advanced cervix cancer: chemotherapy prior to definitive surgery or radiotherapy: a single institutional experience. Australas Radiol 2001, 45:491–495. Lantzsch T, Wolters M, Grimm J, et al.: Sentinel node procedure in Ib cervical cancer: a preliminary series. Brit J Cancer 2001, 85:791–794. Maldur S, Krause N, Kohler C, Schneider A: Sentinel lymph node detection in patients with cervical cancer. Gynecol Oncol 2001, 80:254–257. O’Boyle JD, Coleman RL, Bernstein SG, et al.: Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: a pilot study. Gynecol Oncol 2000, 79:238–243. Kerr IG, Manji MF, Powe J, et al.: Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol Oncol 2001, 81:477–480.